Please update your bookmarks

Kinase News is no longer being updated here, but is instead at http://www.kinasecentral.com

Please update your bookmarks! Archived news is also present on the new site.

Nervianos Aurora kinase effective and safe in Phase I

Data presented at the EORTC-NCI-AACR Symposium show Nerviano’s Aurora kinase inhibitor PHA 739358 to demonstrate good tolerability early signs of efficacy

GlaxoSmithKline chooses not to exercise right to MET/RET/VEGFR2 inhibitor XL184

GlaxoSmithKline has decided not to exercise its option to license MET/RET/VEGFR2 inhibitor from Exelixis

Exelixis PI3K Inhibitor XL147 effective in Phase I

Phase I data presented at the EORTC-NCI-AACR Symposium show Exelixis PI3K inhibitor XL147 to exhibit ‘robust pharmacodynamics’ and preliminary clinical benefit

Exelixis PI3K/mTOR Inhibitor XL765 effective in Phase I

Phase I data presented at the EORTC-NCI-AACR Symposium show Exelixis PI3K/mTOR kinase inhbitor XL765  to show  demonstrate ‘robust pharmacodymanics’

Exelixis Raf kinase inhibitor XL281 effective in Phase I

Phase I data presented at the EORTC-NCI-AACR Symposium show Exelixis RAF kinase inhbitor XL281 to show early signs of clinical activity

Exelixis IGF-1R/Src inhibitor XL228 effective in Phase I

Phase I data presented at the EORTC-NCI-AACR Symposium show Exelixis’ IGF-1R/Src inhibitor  XL228 to show signs of Clinical Benefit inpatients with advanced malignancies

Exelixis MET/VEGFR2/RET inhibitor XL184 effective in Phase I

Phase I data presented at the EORTC-NCI-AACR Symposium show Exelixis MET/VEGFR2/RET inhbitor XL184 demonstrates a 55% Response Rate and 84% Disease Control Rate in Patients with Medullary Thyroid Cancer

Millennium present data on kinase programs at EORTC-NCI-AACR meeting

Data presented at the EORTC NCI AACR meeting detail data and progress on Millennium kinase programs:

MLN8237 – Aurora A  – Phase II trials expected in late 2008/early 2009
TAK-285 – EGFR/HER dual kinase  -  Demonstrated good target specificity, pharmacokinetics and distribution and efficacy in EGFR- and HER2-expressing xenograft models
TAK-593 -VEGF/PDGF – Preclinical data show potent pseudo-irreversibility against VEGF2 & PDGFbeta

EntreMeds Aurora A inhibitor ENMD-2076 effective in vivo

Data presented at the EORTC-NCI-AACR Annual Meeting show EntreMed’ Aurora A kinase inhibitor ENMD-2076 to demonstrate strong antitumor effects in a xenograft model of human colon cancer.